New drug combo shows promise in lung cancer trial

NCT ID NCT05880706

Ongoing Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase II study tests a new drug called BL-B01D1, given alone or with the tablet osimertinib, in 198 adults with advanced non-small cell lung cancer. The goal is to see if the treatment shrinks tumors and to check for side effects. Participants must have a confirmed diagnosis and provide a tumor sample for testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-B01D1 (a drug given by IV) and osimertinib mesylate tablets
What this could lead to: If it works, this could offer a new treatment option for people with advanced non-small cell lung cancer, especially those who have not responded to other therapies.
What could go wrong: This is a Phase II trial, so it is still early. The drug combination may not work better than existing treatments, and side effects could be serious. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, 200433, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.